India News: NEW DELHI: All India Institute Of Medical Sciences (AIIMS) Delhi will start screening children for the indigenous Covaxin trials from Monday, news age.
Updated: Jun 3, 2021, 08:40 AM IST
The paediatric trials for the COVID-19 vaccine manufactured by the Bharat Biotech, Covaxin has started at Patna`s All India Institute of Medical Sciences (AIIMS). Covaxin received the Drugs Controller General of India (DCGI) nod to conduct clinical trials in children on May 11.
Dr VK Paul, Member (Health), Niti Aayog had earlier said, Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years.
The Covaxin trials are also slated to take place in 525 subjects at various sites, including AIIMS, Delhi, and Meditrina Institute of Medical Sciences, Nagpur.
Last Updated:
Republic Top 10 Headlines: COVAXIN s Clinical Trials On Kids; Choksi Denied Bail And More
As India s vaccination drive picks up pace, Bharat Biotech (BBL) on Wednesday started its phase-2 trials of COVAXIN at Patna s AIIMS hospital in Bihar.
COVAXIN s Phase-2 Clinical Trials On Children Aged 2-18 Yrs Begin At Patna s AIIMS
As India s vaccination drive picks up pace, Bharat Biotech (BBL) on Wednesday started its phase-2 trials of COVAXIN at Patna s AIIMS hospital in Bihar. The trial will take place on 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna, and Meditrina Institute of Medical Sciences, Nagpur with two doses administered in an interval of 28 days.
NEW DELHI: All India Institute of Medical Sciences (AIIMS) in Patna on Wednesday began clinical trials of the indigenous Covaxin for children in the age group of 2 to 18 years, according to Prasar Bharati.
Registration for the children to participate in the second phase clinical trial of the Covid-19 vaccine was made open from last week at AIIMS-Patna.
The move came after the Drugs Controller General of India (DGCI) granted permission for the phase 2-3 clinical trial of Covaxin on children. AIIMS-Patna has been selected as one of the sites for the trial along with other institutes such as AIIMS-Delhi and Meditrina Institute of Medical Sciences, Nagpur.